We hereby announce that livedoor Co., Ltd. (hereinafter referred to as q‡livedoorqˆ, President & CEO: Hirofumi Horie), livedoor Securities Co., Ltd. (hereinafter referred to as q‡livedoor Securitiesqˆ, CEO: Hiroshi Nakanishi) and TRANS GENIC INC. (hereinafter referred to as q‡TRANS GENICqˆ, CEO: Masahiro Koreishi) have on December 26, 2005 concluded an agreement concerning comprehensive business tie-up with bio-related business conducted by livedoor Group.

livedoor Group is conducting online portal and finance business as its core enterprise, and has been expanding its business by several strategies, such as M&A. TRANS GENIC is a university-born bio-venture company providing valuable genetic information and antibodies for the development of pharmaceuticals and diagnostics.

In its finance business, livedoor Group operates bio funds and invests in bio-related enterprises. On this occasion, livedoor Group and TRANS GENIC have reached agreement on a comprehensive business tie-up with aforementioned bio-related business.

The following aspects have been resolved thus far; livedoor Group and TRANS GENIC continue to conclude contracts, based on this concluded agreement, regarding comprehensive business alliance.

qÎqc livedoor and TRANS GENIC will co-invest in bio funds. livedoor will be in charge of managing the funds, and TRANS GENIC will support activities related to finding, evaluating and selecting investing firms.

qÏqcTRANS GENIC will give comprehensive advice to livedoor Group regarding finding, evaluating and selecting object enterprises in its activities of investing in bio-related companies and M&A.

Under this concluded agreement, in its activities related to finding, evaluating and selecting investing firms, livedoor Group will receive support for object companies, and will obtain information and access to the network from TRANS GENIC. As a consequence, livedoor Group expects increased expansion of its investing firms and investment income. Meanwhile, TRANS GENIC intends to reinforce cooperation with livedoor Group so as to gain more information regarding technologies in life science and to pursue business affiliations and capital tie-ups under consideration.